Hemangiomas are characterized histologically by high endothelial cell turnover, and their clinical "life cycle" includes proliferative, plateau, and involution phases. Hemangiomas are further characterized by cell markers (GLUT-I , merosin, Lewis Y) that are otherwise found only in human placental tissue . Most other vascular anomalies are properly termed "malformations," which are characterized by normal endothelial cell turnover and abnormal gross vascular anatomy.
With interest, I have read in ENT JOURNAL two recent articles that unfortunately perpetuate obsolete terminology and misclassify vascular anomalies in the head and neck:
• In the January 2006 PATHOLOGY CLINIC, Thompson addresses "lymphangioma" and describes cystic, capillary, 354 and cavernous subtypes. ' However, none ofthese terms is recognized in the current classification ofvascular anomalies. Since the suffix -oma implies a proliferating lesion , such masses are more appropriately termed " lymphatic malformations." Subtypes oflymphatic malformations are macrocystic, microcystic, and mixed , and they are further categorized by their anatomic location.
• Monin et al are to be commended for a skillful approach to resection of a vascular lesion from a difficult-to-reach location, as described in the September 2005 issue.' However, the mass they described as a "venous hemangioma" is more appropriately termed a "venous malformation," especially since a hemangioma would likely have involuted completely in a patient aged 28 years.
Referral for treatment ofvascular anomalies is dependent on an accurate diagnosis of these lesions by the primary care physician. Because the management of vascular anomalies frequently crosses medical disciplines, specialists must agree on a uniform terminology in order to facilitate communication and develop treatment protocols. Otolaryngologists should strive for precision in describing vascular anomalies. Dr. Darrow refers to a 24-year-old clinical classification system that was based on endothelial proliferation in a small series of lesions and was apparently meant to classify congenital lesions. ' In that classification system, Mulliken and Glowacki primarily distinguished between hem angiom as (proliferative) and ma lformations (nonproliferative). Th ey inclu ded five types of hem angiom a and five types of malformation. T he mai n hem angiom a was the j uveni le ty pe , also ca lled the " infantile" or "cellular" type. Mulliken and Glowacki determined that the j uven ile type may go through a pro liferation and invo lutio n cyc le, and they ex trapolated that idea to all hemangiomas. However, the vast majority of hemangiomas do not progress through such a cycle.
David
Mulliken and Glowacki were very focused on certain lesions ofthe head and neck in the congenital setting. They offered a simplified approach, which Dr. Thompson notes that he does not prefer. It is true that some pathologists like ly did call port-wine stains "hemangiomas," even though they are malformations. Mu lliken and Glowacki called attention to that misclassification (actually misdiagnosis) . By no means was it then, nor is it now, app licab le to the complete and accurate classification of bodily vascu lar lesions.
The classifica tio n system used today takes into accou nt adva nces that have occurred over the pas t severa l 3 5 6 decades. There are now well over 30 different types oftrue hemangioma, some ofwhich have proven by cytogenetic studies to be neoplastic. The latest pathology classifications-" of vascular entities, combining blood vascular and lymphatic lesions, includes six categories: hamartomas, malformations, dilations of preex ist ing vessels (e .g., telangiectasias and angiokeratomas), hyperplasias (e.g. , baci llary angiomatosis and papi llary endothel ial hyperplas ia), benign neoplasms (e .g., ma ny hemangioma subtypes such as ho bnail, microvenular, sinusoidal), an d ma ligna ncies (fo ur hemangioend otheliomas, severaltypes of angiosarcoma, and Ka posi's sarcoma) . A nu mber of these entities, particular ly the benign lesi ons, are associated w ith various sy ndromes. For the record, wh ile many ben ign hemangiomas may have a proliferative element (now identified by Ki-67/MIB-l staining), there are also hemangiomas with a very low rate of proliferation and malformations with obvious proliferative foci secondary to induction by high blood flow, Likewise, while many lymphatic lesions ("lymphangiomas") are malformations, they may have proliferative areas, and while ot her lesions are acquired, still others are neoplastic (e.g. , acquired proliferative lymphangiomas). It is not correct to assume that all forms of lymphangioma are malformations.
In the case we described in our article, the lesion was a neoplasm with a capsule and dilated vascular spaces, which happened to be surrounded by smooth muscle." In fact , if the smooth musc le had not been noticed and co nfirmed wi th smooth-muscle actin immu nostai ning, the lesion wou ld have been called a "caverno us hem angioma" (itse lf d istinct from a malformation ). So me path ologists might have diagnosed our lesion as an ang iomyoma because it also had th is combi nation; however, it was more aki n to a leiomyoma with abundant vessels and lacked the arrangement seen in venous hemang iomas. Nevertheless, our lesion was not a ma lformation. Malformations, wh ich are common ly seen by one of us (lSJ.B., a soft-tissue pathologist), are unencapsulated groups of vessels, often with both arteries and veins. The structures are frequently dysmorphic , meaning that each vascular channel has variab ly thick and thin muscle walls. Furthermore, the walls ofthe veins have a characteristic bundled structure, unlike the neopl asm in our patient. We agree that malformations are not neop lastic, but we emphasize that the lesion in our pat ient was not a ma lformat ion, nor was it misclass ified or misdiagnosed.
Classifications change with time and understanding. W hat seems c lear is that class ifications used in different specialties may differ. Co nfus ion may ste m fro m
